For FY23, we have removed forecast earnings from the sale of remestemcel-L. Approval is probably unlikely before 30 June 2023. Even though the BLA review is subject to an accelerated review, the FDA is likely to require a site inspection of the Lonza manufacturing facility in Singapore prior to an approval. We have also adjusted the cost base based on the latest data from the quarterly cash flow.
Aloha.
2023 The Final Countdown, page-28
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.073(6.68%) |
Mkt cap ! $1.324B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.20 | $1.11 | $18.65M | 15.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 156475 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 25007 | 7 |
View Market Depth
| Last trade - 15.50pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.073 ( 5.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.20 | $1.12 | 3730649 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MSB (ASX) Chart |